Pharmacological treatment of pulmonary fibrosis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Won-Il | - |
dc.date.accessioned | 2023-08-16T08:14:21Z | - |
dc.date.available | 2023-08-16T08:14:21Z | - |
dc.date.created | 2023-07-19 | - |
dc.date.issued | 2020-01 | - |
dc.identifier.issn | 1975-8456 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/189325 | - |
dc.description.abstract | Idiopathic pulmonary fibrosis (IPF) is a condition that has been described as alveolar collapse and thickening, which correlate with dysregulated surfactant production and injury to type 2 alveolar cells. As resolution of chest computed tomography has improved, especially with the development of high-resolution computed tomography (HRCT), the diagnostic measures adopted for pulmonary fibrosis has gradually shifted from biopsy to HRCT. This shift towards HRCT has aided in diagnostic evaluation and detection of the therapeutic and adverse effects of drugs for pulmonary fibrosis. Further, after the endpoint was changed to forced vital capacity, significant improvements are being observed in clinical trial outcomes. Currently active clinical trials are replacing lung biopsy with HRCT. In 2014, pirfenidone and nintedanib gained approval for tandem use in patients with IPF. These drugs were found to not only reduce the progression of pulmonary fibrosis, but also the acute exacerbation and mortality associated with the condition. These drugs showed consistent benefits regardless of the severity of patients' symptoms. Additionally, both nintedanib and pirfenidone were found to be effective in patients with advanced pulmonary fibrosis that was not classified as IPF. Nintedanib has been shown to reduce forced vital capacity in interstitial lung diseases associated with systemic sclerosis. In the next three to five years, many changes in treatment are expected, not only for IPF, but also for the entire spectrum of pulmonary fibrotic diseases. Pirfenidone and nintedanib are now considered standard treatments for IPF and few other fibrotic lung diseases. Clinicians treating patients with pulmonary fibrosis should keep themselves updated with the results of clinical trials that are currently underway. | - |
dc.language | 한국어 | - |
dc.language.iso | ko | - |
dc.publisher | KOREAN MEDICAL ASSOC | - |
dc.title | Pharmacological treatment of pulmonary fibrosis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Won-Il | - |
dc.identifier.doi | 10.5124/jkma.2020.63.1.47 | - |
dc.identifier.scopusid | 2-s2.0-85084790044 | - |
dc.identifier.wosid | 000508001600007 | - |
dc.identifier.bibliographicCitation | JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, v.63, no.1, pp.47 - 55 | - |
dc.relation.isPartOf | JOURNAL OF THE KOREAN MEDICAL ASSOCIATION | - |
dc.citation.title | JOURNAL OF THE KOREAN MEDICAL ASSOCIATION | - |
dc.citation.volume | 63 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 47 | - |
dc.citation.endPage | 55 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002549483 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | INTERSTITIAL LUNG ABNORMALITIES | - |
dc.subject.keywordPlus | ACUTE EXACERBATION | - |
dc.subject.keywordPlus | PIRFENIDONE | - |
dc.subject.keywordPlus | NINTEDANIB | - |
dc.subject.keywordPlus | DIAGNOSIS | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | CAPACITY | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | UPDATE | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordAuthor | Idiopathic pulmonary fibrosis | - |
dc.subject.keywordAuthor | Interstitial lung diseases | - |
dc.subject.keywordAuthor | Nintedanib | - |
dc.subject.keywordAuthor | Pirfenidone | - |
dc.identifier.url | https://synapse.koreamed.org/articles/1141002 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.